Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Merck KGaA that it expects to be completed over the next three months. The project will involve pre-clinical and clinical modelling and simulation of anti-cancer regimens involving combinations of DNA damage/ repair agents and follows on from previous projects commissioned by Merck KGaA.
Physiomics CEO, Dr Jim Millen, commented:
"We are pleased that this longstanding client has once again chosen Physiomics as a partner for outsourced modelling. We look forward to the possibility of further projects with Merck during the current financial year."